Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Trastuzumab Emtansine
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial -
Trastuzumab and neratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Breast Cancer; HER2-positive; Metastatic
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced or Metastatic Breast Cancer
1 trial -
Trastuzumab emtansine
Hoffmann-La Roche
Breast Cancer
3 trials -
Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of β₯6 hours between doses) for three months.
The First People's Hospital of Lianyungang
Post-stroke Epilepsy
1 trial -
Trelagliptin 25 mg
Takeda
Type 2 Diabetes Mellitus
1 trial -
Tremelimumab
AstraZeneca
Hepatocellular Carcinoma
1 trial -
Treprostinil, The Placebo Nebuliser Solution is a solution dosage form for nebulisation identical to Treprostinil Nebuliser Solution drug product except for the absence of the treprostinil drug substance.
United Therapeutics Europe Ltd
Progressive Pulmonary Fibrosis
1 trial -
Trichosanthes root
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diabetes Mellitus
1 trial -
Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)
United Therapeutics Europe Ltd
Nausea
1 trial -
Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
AstraZeneca AB
Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)
1 trial -
Trulicity 0.75 mg solution for injection in pre-filled pen
The George Institute
Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantation
1 trial -
Trulicity 0.75 mg solution for injection in pre-filled pen
The George Institute
Preventive treatment of post-kidney transplant diabetes
1 trial -
Truxima 500 mg concentrate for solution for infusion, Cyclophosphamide Injection 500 mg., Epcoritamab (GEN3013), Vincristine Sulfate 1 mg/ml solution for injection, Doxorubicinhydrochlorid Bendalis 2 mg/ml InjektionslΓΆsung, Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, Prednisone Zentiva 5 mg compresse
AbbVie Deutschland GmbH & Co. KG
Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
UDCA
The First People's Hospital of Lianyungang
Diabetes Mellitus
1 trial -
UVEDOSE 100 000 UI, solution buvable en ampoule
Novo Nordisk A/S
Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia
1 trial -
UX111
ABEONA THERAPEUTICS INC.
MPS IIIA
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis
3 trials -
Ublituximab
TG THERAPEUTICS, INC.
Diffuse Large B-Cell Lymphoma
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis (RMS)
3 trials -
Ublituximab
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
5 trials -
Ublituximab, ublituximab
TG THERAPEUTICS, INC.
Relapsing forms of Multiple Sclerosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources